HRP20161022T1 - TERAPIJSKA UPORABA PROTEINA ß2-MIKROGLOBULINA - Google Patents
TERAPIJSKA UPORABA PROTEINA ß2-MIKROGLOBULINA Download PDFInfo
- Publication number
- HRP20161022T1 HRP20161022T1 HRP20161022TT HRP20161022T HRP20161022T1 HR P20161022 T1 HRP20161022 T1 HR P20161022T1 HR P20161022T T HRP20161022T T HR P20161022TT HR P20161022 T HRP20161022 T HR P20161022T HR P20161022 T1 HRP20161022 T1 HR P20161022T1
- Authority
- HR
- Croatia
- Prior art keywords
- microglobulin
- pharmaceutical product
- protein
- mhc
- autoimmune disease
- Prior art date
Links
- 102000015736 beta 2-Microglobulin Human genes 0.000 title claims 18
- 108010081355 beta 2-Microglobulin Proteins 0.000 title claims 18
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 229940127557 pharmaceutical product Drugs 0.000 claims 16
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 102000003839 Human Proteins Human genes 0.000 claims 4
- 108090000144 Human Proteins Proteins 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 102000047279 human B2M Human genes 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000018628 immunodeficiency 43 Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
Claims (21)
1. Farmaceutski proizvod, karakteriziran na način da se sastoji od β2-mikroglobulina ili funkcionalne varijante tog proteina koji pokazuje najmanje 70% identičnosti s ljudskim proteinom β2-mikroglobulinom, kao aktivnim sastojkom, u farmaceutski prihvatljivom nosaču, pri čemu je navedeni farmaceutski prihvatljivi nosač liposom.
2. Farmaceutski proizvod u skladu s patentnim zahtjevom 1, pri čemu je navedeni aktivni sastojak ljudski protein β2-mikroglobulin.
3. Farmaceutski proizvod u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni aktivni sastojak funkcionalna varijanta proteina β2-mikroglobulina koji pokazuje najmanje 80%, a poželjno 90% identičnosti s ljudskim proteinom β2-mikroglobulinom.
4. Farmaceutski proizvod karakteriziran na način da se sastoji od β2-mikroglobulina ili funkcionalne varijante tog proteina koji pokazuje najmanje 70% identičnosti s ljudskim proteinom β2-mikroglobulinom, kao aktivnim sastojkom, u farmaceutski prihvatljivom nosaču, za uporabu u liječenju autoimune bolesti.
5. Farmaceutski sastav u skladu s patentnim zahtjevom 4, pri čemu je navedeni aktivni sastojak ljudski protein β2-mikroglobulin.
6. Farmaceutski sastav u skladu s patentnim zahtjevom 4 ili 5, pri čemu je navedeni aktivni sastojak funkcionalna varijanta proteina β2-mikroglobulina koji pokazuje najmanje 80%, a poželjno 90% identičnosti s ljudskim proteinom β2-mikroglobulinom.
7. Farmaceutski proizvod za uporabu u skladu s patentnim zahtjevima 4, 5 ili 6, karakteriziran na način da je tretirana autoimuna bolest reumatoidni poliartritis, sustavni eritematozni lupus, Sjögrenov sindrom, skleroderma, fibromijalgija, miozitis, ankilozantni spondilitis, o inzulinu ovisni dijabetes tipa I, Hashimotov tireoiditis, Addisonova bolest, Chronova bolest, celijakija, multipla skleroza ili amiotropna lateralna skleroza.
8. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u liječenju amiotropne lateralne skleroze (ALS).
9. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u liječenju multiple skleroze.
10. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u liječenju Chronove bolesti.
11. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u liječenju reumatoidnog poliartritisa.
12. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u liječenju o inzulinu ovisnog dijabetesa tipa I.
13. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u povećavanju koncentracije β2-mikroglobulina u krvi do koncentracije sadržane između 2.5 i 12 mg/L, poželjno između 3 i 8 mg/L, poželjnije između 3 i 5 mg/L kod pacijenta koji pati od autoimune bolesti.
14. Farmaceutski proizvod za uporabu u skladu s bilo kojim od patentnih zahtjeva 4, 5 ili 6 u obnavljanju normalnog molarnog omjera HC/β2-mikroglobulina unutar membrane MHC-I kompleksa kod pacijenta koji pati od autoimune bolesti.
15. Farmaceutski proizvod za uporabu u skladu s jednim od patentnih zahtjeva 4, 5 ili 6 u sprječavanju pojave nedostatka β2-mikroglobulina u MHC-I kompleksu kod pacijenta koji pati od autoimune bolesti.
16. Farmaceutski proizvod za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, karakteriziran na način da se sastoji od liposoma napunjenih β2-mikroglobulinom ili funkcionalnom varijantom toga proteina.
17. Farmaceutski proizvod u skladu s jednim od patentnih zahtjeva 1 do 3, karakteriziran na način da je β2-mikroglobulin pripremljen u fiziološkoj otopini i prethodno inkubiran ex-vivo u kontaktu s krvlju, serumom ili limfocitima pacijenta kojeg treba liječiti.
18. Sastav obuhvaća farmaceutski proizvod u skladu s jednim od patentnih zahtjeva 1 do 3.
19. Metoda za dijagnosticiranje autoimune bolesti, karakterizirana na način da obuhvaća korak koji se sastoji od određivanja unutarstaničnog ili membranskog omjera HC/β2-mikroglobulina MHC-I kompleksa u stanicama pacijenta.
20. Metoda za dijagnosticiranje u skladu s patentnim zahtjevom 19, karakterizirana na način da je omjer HC/β2-mikroglobulina MHC-I kompleksa membranski omjer.
21. Metoda u skladu s patentnim zahtjevom 20, karakterizirana na način da obuhvaća korake:
i) ekstrahiranje MHC-I kompleksa iz stanica, poželjno limfocita, od pacijenta kojeg treba pregledati na postojanje autoimune bolesti;
ii) određivanje odgovarajućih količina HC i β2-mikroglobulina sadržanih u navedenim MHC-I kompleksima;
iii) uspostavljanje molarnog omjera HC/β2-mikroglobulina navedenog MHC-I kompleksa;
iv) usporedbu dobivenog omjera HC/β2-mikroglobulina s omjerom kontrolnog uzorka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10290188A EP2374470A1 (fr) | 2010-04-08 | 2010-04-08 | Utilisation thérapeutique de la protéine Beta2m |
| US34661710P | 2010-05-20 | 2010-05-20 | |
| PCT/IB2011/051476 WO2011125029A1 (en) | 2010-04-08 | 2011-04-06 | THERAPEUTIC USE OF THE ß2m PROTEIN |
| EP11717774.1A EP2555790B1 (en) | 2010-04-08 | 2011-04-06 | THERAPEUTIC USE OF THE ß2-MICROGLOBULIN PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161022T1 true HRP20161022T1 (hr) | 2016-10-21 |
Family
ID=42315462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161022TT HRP20161022T1 (hr) | 2010-04-08 | 2016-08-16 | TERAPIJSKA UPORABA PROTEINA ß2-MIKROGLOBULINA |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130017212A1 (hr) |
| EP (2) | EP2374470A1 (hr) |
| JP (3) | JP5955833B2 (hr) |
| KR (1) | KR101889564B1 (hr) |
| CN (2) | CN108159398A (hr) |
| BR (1) | BR112012025537A2 (hr) |
| CA (1) | CA2793940C (hr) |
| CY (1) | CY1117968T1 (hr) |
| DK (1) | DK2555790T3 (hr) |
| ES (1) | ES2588710T3 (hr) |
| HR (1) | HRP20161022T1 (hr) |
| HU (1) | HUE030420T2 (hr) |
| LT (1) | LT2555790T (hr) |
| PL (1) | PL2555790T3 (hr) |
| PT (1) | PT2555790T (hr) |
| RS (1) | RS55121B1 (hr) |
| RU (1) | RU2582389C2 (hr) |
| SI (1) | SI2555790T1 (hr) |
| SM (1) | SMT201600301B (hr) |
| WO (1) | WO2011125029A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2374470A1 (fr) * | 2010-04-08 | 2011-10-12 | Beta Innov | Utilisation thérapeutique de la protéine Beta2m |
| CN102716379A (zh) * | 2012-06-25 | 2012-10-10 | 毕建飞 | 一种治疗强直性脊柱炎的中药组合物 |
| CN116515000A (zh) * | 2023-06-30 | 2023-08-01 | 迦进生物医药(上海)有限公司 | Hfe融合蛋白及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| ATE147990T1 (de) * | 1990-05-10 | 1997-02-15 | Dana Farber Cancer Inst Inc | Erhöhung der assoziation exogener peptide mit mhci-molekülen auf zellen des immunsystems |
| JPH07118163A (ja) * | 1993-10-21 | 1995-05-09 | Mitsui Toatsu Chem Inc | β２−ミクログロブリンを含有する組成物 |
| FR2735984B1 (fr) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic |
| US6100891A (en) | 1998-06-09 | 2000-08-08 | Teledirect International, Inc. | Call center agent interface and development tool |
| CA2383737C (en) * | 1999-09-08 | 2011-01-18 | Transgene S.A. | Muc-1 derived peptides |
| WO2002024929A2 (en) * | 2000-09-22 | 2002-03-28 | Ramot At Tel Aviv University Ltd | A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS |
| GB0115071D0 (en) * | 2001-06-20 | 2001-08-15 | Avidex Ltd | Substances |
| WO2003029475A1 (en) * | 2001-09-28 | 2003-04-10 | Dnavec Research Inc. | MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF |
| WO2003086307A2 (en) * | 2002-04-12 | 2003-10-23 | The Board Of Trustees Of The University Of Arkansas | β2-MICROGLOBILIN (β2m) AND ANTI-β2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS |
| US20040127445A1 (en) | 2002-08-28 | 2004-07-01 | Chondrogene Limited | Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation |
| AU2004275649A1 (en) | 2003-09-30 | 2005-04-07 | Snow Brand Milk Products Co., Ltd. | Agent for promoting osteogenesis and/or inhibiting bone resorption |
| JP4740531B2 (ja) * | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| EP2374470A1 (fr) * | 2010-04-08 | 2011-10-12 | Beta Innov | Utilisation thérapeutique de la protéine Beta2m |
| CN112303586A (zh) | 2019-07-31 | 2021-02-02 | 华域视觉科技(上海)有限公司 | 车辆照明装置、车辆大灯及车辆 |
-
2010
- 2010-04-08 EP EP10290188A patent/EP2374470A1/fr not_active Withdrawn
-
2011
- 2011-04-06 CA CA2793940A patent/CA2793940C/en active Active
- 2011-04-06 BR BR112012025537A patent/BR112012025537A2/pt not_active Application Discontinuation
- 2011-04-06 PL PL11717774.1T patent/PL2555790T3/pl unknown
- 2011-04-06 WO PCT/IB2011/051476 patent/WO2011125029A1/en active Application Filing
- 2011-04-06 CN CN201711451897.XA patent/CN108159398A/zh active Pending
- 2011-04-06 CN CN2011800209596A patent/CN102869368A/zh active Pending
- 2011-04-06 JP JP2013503207A patent/JP5955833B2/ja active Active
- 2011-04-06 DK DK11717774.1T patent/DK2555790T3/en active
- 2011-04-06 EP EP11717774.1A patent/EP2555790B1/en active Active
- 2011-04-06 PT PT117177741T patent/PT2555790T/pt unknown
- 2011-04-06 US US13/636,438 patent/US20130017212A1/en not_active Abandoned
- 2011-04-06 SI SI201130922A patent/SI2555790T1/sl unknown
- 2011-04-06 ES ES11717774.1T patent/ES2588710T3/es active Active
- 2011-04-06 HU HUE11717774A patent/HUE030420T2/en unknown
- 2011-04-06 LT LTEP11717774.1T patent/LT2555790T/lt unknown
- 2011-04-06 RS RS20160725A patent/RS55121B1/sr unknown
- 2011-04-06 RU RU2012147460/15A patent/RU2582389C2/ru active
- 2011-04-06 KR KR1020127029186A patent/KR101889564B1/ko active IP Right Grant
-
2016
- 2016-02-05 JP JP2016020393A patent/JP2016145208A/ja active Pending
- 2016-08-16 HR HRP20161022TT patent/HRP20161022T1/hr unknown
- 2016-09-05 CY CY20161100870T patent/CY1117968T1/el unknown
- 2016-09-06 SM SM201600301T patent/SMT201600301B/it unknown
- 2016-10-20 US US15/298,757 patent/US11484571B2/en active Active
-
2017
- 2017-12-27 JP JP2017250624A patent/JP6703973B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013523808A (ja) | 2013-06-17 |
| EP2555790A1 (en) | 2013-02-13 |
| JP5955833B2 (ja) | 2016-07-20 |
| CY1117968T1 (el) | 2017-05-17 |
| CA2793940C (en) | 2019-07-09 |
| CA2793940A1 (en) | 2011-10-13 |
| EP2374470A1 (fr) | 2011-10-12 |
| CN102869368A (zh) | 2013-01-09 |
| PL2555790T3 (pl) | 2016-12-30 |
| LT2555790T (lt) | 2016-09-12 |
| CN108159398A (zh) | 2018-06-15 |
| US20130017212A1 (en) | 2013-01-17 |
| SI2555790T1 (sl) | 2016-09-30 |
| US11484571B2 (en) | 2022-11-01 |
| RS55121B1 (sr) | 2016-12-30 |
| US20170035846A1 (en) | 2017-02-09 |
| EP2555790B1 (en) | 2016-06-08 |
| JP6703973B2 (ja) | 2020-06-03 |
| JP2016145208A (ja) | 2016-08-12 |
| JP2018076356A (ja) | 2018-05-17 |
| KR20130086133A (ko) | 2013-07-31 |
| HUE030420T2 (en) | 2017-05-29 |
| ES2588710T3 (es) | 2016-11-04 |
| WO2011125029A1 (en) | 2011-10-13 |
| RU2582389C2 (ru) | 2016-04-27 |
| PT2555790T (pt) | 2016-09-09 |
| DK2555790T3 (en) | 2016-09-12 |
| SMT201600301B (it) | 2016-11-10 |
| RU2012147460A (ru) | 2014-05-20 |
| KR101889564B1 (ko) | 2018-08-17 |
| BR112012025537A2 (pt) | 2016-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ayuk et al. | How should hypomagnesaemia be investigated and treated? | |
| Joris et al. | Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial | |
| Buemi et al. | The effect of two different protocols of potassium haemodiafiltration on QT dispersion | |
| Pillon et al. | Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis | |
| Dwyer et al. | Nutritional status affects quality of life in Hemodialysis (HEMO) Study patients at baseline | |
| Price et al. | Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes | |
| Stoner | Management of serious cardiac adverse effects of antipsychotic medications | |
| Santos et al. | Association between the level of quality of life and nutritional status in patients undergoing chronic renal hemodialysis | |
| Uzu et al. | Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy | |
| HRP20161022T1 (hr) | TERAPIJSKA UPORABA PROTEINA ß2-MIKROGLOBULINA | |
| Parker et al. | Pathological alterations of cation movements in red blood cells | |
| Silva et al. | Waist-to-height ratio: an accurate anthropometric index of abdominal adiposity and a predictor of high HOMA-IR values in nondialyzed chronic kidney disease patients | |
| Bolasco | Hemodialysis—nutritional flaws in diagnosis and prescriptions. Could amino acid losses be the sharpest “sword of damocles”? | |
| Dalamaga et al. | Hypocalcemia, hypomagnesemia, and hypokalemia following hydrofluoric acid chemical injury | |
| Zhou et al. | Effects of increasing diffusive sodium removal on blood pressure control in hemodialysis patients with optimal dry weight | |
| Cherian et al. | Tight glycemic control regulates fibronectin expression and basement membrane thickening in retinal and glomerular capillaries of diabetic rats | |
| Sung et al. | Reliability and validity of the function in sitting test in nonambulatory individuals with multiple sclerosis | |
| Dumler et al. | Prospective nutritional surveillance using bioelectrical impedance in chronic kidney disease patients | |
| Zsom et al. | Subjective global assessment of nutrition, dialysis quality, and the theory of the scientific method in Nephrology practice | |
| Oliveira et al. | Metabolic acidosis and its association with nutritional status in hemodialysis | |
| Stolic et al. | Impact of metabolic syndrome and malnutrition on mortality in chronic hemodialysis patients | |
| Horoz et al. | Crataegus orientalis associated multiorgan hypersensitivity reaction and acute renal failure | |
| Soliman et al. | Does Vitamin D therapy affect hematological indices in adolescents with vitamin D deficiency? | |
| Druid et al. | Fatal injections of heroin. Interpretation of toxicological findings in multiple specimens | |
| Chan et al. | Increased leptin concentrations and lack of gender difference in Type 2 diabetic patients with nephropathy |